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Supplemental	Methods	1.	Data	Sources	and	Search	Strategies	
We	performed	a	systematic	literature	review	on	the	risk	of	atrial	fibrillation	across	the	full	TSH	range	in	
MEDLINE	and	EMBASE	databases	without	language	restriction	from	inception	to	July	27,	2016.	We	did	our	
search	on	an	Ovid	(MEDLINE)	server	by	using	broadly	defined	Medical	Subject	Headings	(MeSH):	thyroid	
diseases,	hypothyroidism,	hyperthyroidism,	thyroid	hormones,	thyrotropin,	atrial	fibrillation,	arrhythmia;	and	
the	following	keywords:	subclinical	hypothyroidism,	subclinical	hyperthyroidism,	subclinical	dysthyroidism,	
subclinical	thyroid,	and	euthyroid.	We	used	the	filter	designed	by	knowledge	information	specialists	from	BMJ	
to	select	prospective	studies	(MEDLINE	cohort-study	filter)1	but	without	their	year	limitation.	A	search	in	
EMBASE	was	done	using	similar	terms.	We	also	conducted	a	manual	literature	search	with	review	of	expert	
papers	in	the	field	and	screened	bibliographies	from	retrieved	articles.		
	 	
Supplemental	Methods	2.	Study	Quality	Assessment	
Following	individual	criteria	of	the	Newcastle-Ottawa	Quality	Assessment	Scale2	were	assessed:	1-2)	
representativeness	of	the	exposed/unexposed	cohort	(populations-based	vs.	convenience	based),	3)	
ascertainment	of	exposure	(thyroid	function	measurement),	4)	demonstration	that	outcome	of	interest	(atrial	
fibrillation)	was	not	present	at	start	of	study,	5)	availability	of	relevant	confounders	for	adjustment,	6)	objective	
assessment	of	outcome	(assessment	of	atrial	fibrillation	by	electrocardiogram),	7)	adequate	length	of	follow-up	
period	(>5	years),	and	8)	loss	of	follow-up	(<5%).	Two	authors	independently	assessed	study	quality	(C.B.	and	
C.F.).	
	 	
Supplemental	Table	1.	Definition	of	Baseline	Covariates	
Study	 Smoking	 Diabetes	 Prevalent	Cardiovascular	Disease		
Cardiovascular	Health	
Study4	
Self-reported	never,	former,	or	
current	smoking	(³100	
cigarettes	in	entire	life)	
Fasting	glucose	level	of	³126mg/dL	or	use	of	
hypoglycemic	medication	
History	of	myocardial	infarction	or	angina	or	CABG	or	angioplasty	
or	stroke	or	TIA	(adjudicated)	
Health	ABC	Study9	 Self-reported	never,	former,	or	
current	smoking	(³100	
cigarettes	in	entire	life)	
Self-reported	diagnosis	of	diabetes	or	use	of	
hypoglycemic	medication	
Self-reported	history	of	myocardial	infarction	or	angina	with	use	
of	antianginal	medications	or	CABG	or	angioplasty	or	stroke	or	
TIA		
Osteoporotic	Fractures	
in	Men	(MrOS)	Study10	
Self-reported	never,	former,	or	
current	smoking	
Self-reported	diagnosis	of	diabetes	 Self-reported	myocardial	infarction	or	stroke		
Bari	Study11	 Self-reported	non-smoker	or	
current	smoker	(regular	
smoking	within	last	30	days)	
Physician	diagnosis	of	diabetes	 History	of	myocardial	infarction	or	angina	or	CABG	or	angioplasty	
or	stroke	(assessed	by	review	of	medical	records)	
Leiden	85-plus	Study12	 Self-reported	never,	former,	or	
current	smoking	
Physician	diagnosis	of	diabetes	or	use	of	
hypoglycemic	medication	
History	of	myocardial	infarction	or	angina	or	stroke	(assessed	by	
review	of	medical	records,	physician	or	self-report,	and	ECG)	
SHIP13	 Self-reported	never,	former,	or	
current	smoking	
Self-reported	or	physician	diagnosis	of	
diabetes	
Self-reported	myocardial	infarction	or	CABG	or	stroke		
InChianti	Study14	 Self-reported	never,	former,	or	
current	smoking	(if	at	least	1	
year	of	cigarette	smoking)	
Fasting	blood	glucose	>140	mg/dL	or	
glucosuria	
History	of	myocardial	infarction	or	angina	or	perfusion	
deficit/asynergy	in	scintigraphy	or	severe	stenosis	in	coronary	
angiography	or	CABG	or	angioplasty	or	stroke	(adjudicated)	
Rotterdam	Study8	 Self-reported	never,	former,	or	
current	smoking	
Random	or	post-load	serum	glucose	level	of	
200mg/dL	or	higher,	or	use	of	hypoglycemic	
medication	
History	of	myocardial	infarction	or	revascularization	or	stroke	
(assessed	by	self-report,	ECG,	review	of	nationwide	Medical	
Registry,	screening	of	physician	records)	
PROSPER	Study15	 Self-reported	never,	current,	or	
former	smoking	
Self-reported	diagnosis	of	diabetes	or	use	of	
hypoglycemic	drugs	or	fasting	blood	glucose	
of	7.0mmol/l	or	11.1mmol/l	or	greater	when	
fasting	status	was	uncertain	
Physician	diagnosis	of	vascular	disease	or	myocardial	infarction	
or	angina	or	CABG	or	angioplasty	or	stroke	or	TIA		
EPIC-Norfolk	Study16	 Self-reported	never,	former,	or	
current	smoking	(if	³1	cigarette	
a	day	for	³1	year)	
Self-reported	diagnosis	of	diabetes	 Self-reported	myocardial	infarction	or	stroke		
Busselton	Health	Study17	 Self-reported	never,	former,	or	
current	smoking	
Self-reported	diagnosis	of	diabetes,	use	of	
hypoglycemic	drugs,	or	glucose	level	>200	
mg/dL	2	hours	after	glucose	load	
History	of	myocardial	infarction	or	angina	(assessed	by	self-
reported	confirmation	of	physician	diagnosis,	Rose	
questionnaire,	ECG)	
	Abbreviations:	CABG,	coronary	artery	bypass	surgery;	ECG,	electrocardiogram;	TIA,	transient	ischemic	attack	
	Supplemental	Table	2.	Studies	Excluded	after	Full	Text	Screening	
Reason	for	exclusion	 References	
Review,	meeting	abstract,	poster	or	
editorial	
Erichsen	R,	Christiansen	CF,	Froslev	T,	Jacobsen	J,	Sorensen	HT.	Intravenous	bisphosphonate	therapy	and	risk	of	atrial	fibrillation	in	
cancer	patients.	Pharmacoepidemiology	and	Drug	Safety.	2011;20((Erichsen	R.;	Christiansen	C.F.;	Froslev	T.;	Jacobsen	J.;	
Sorensen	H.T.)	Department	of	Clinical	Epidemiology,	Aarhus	University	Hospital,	Aarhus	N,	Denmark):S121.	
Kim	SC,	Liu	J,	Solomon	DH.	The	risk	of	atrial	fibrillation	in	patients	with	rheumatoid	arthritis	compared	to	the	general	population:	A	
large	cohort	study.	Arthritis	and	Rheumatism.	2012;64((Kim	S.C.)	Brigham	and	Women's	Hospital,	Boston,	United	
States):S722.	
Nanchen	D,	Gussekloo	J,	Westendorp	RGJ,	et	al.	Subclinical	thyroid	dysfunction	and	the	risk	of	heart	failure,	other	cardiovascular	
events	and	mortality	in	the	elderly.	Journal	of	General	Internal	Medicine.	2011;26((Nanchen	D.;	Gussekloo	J.;	Westendorp	
R.G.J.;	Jukema	J.W.;	Trompet	S.;	Mooijaart	S.P.;	De	Craen	A.J.M.)	Leiden	University	Medical	Center,	Leiden,	
Netherlands):S140.	
Stojanovic	M,	Sabljak	V,	Markovic	D,	Ladjevic	N,	Zivaljevic	V,	Kalezic	N.	New	onset	atrial	fibrillation	during	goitre	surgery.	European	
Journal	of	Anaesthesiology.	2013;30((Stojanovic	M.;	Sabljak	V.;	Markovic	D.;	Ladjevic	N.;	Zivaljevic	V.;	Kalezic	N.)	Clinical	
Centre	of	Serbia,	Dept	of	Anaesthesiology,	Belgrade,	Serbia):28.	
Chelazzi	C,	Giugni	D,	Villa	G,	De	Gaudio	R.	Postoperative	atrial	fibrillation	among	non	cardio-thoracic	surgical	patients:	Associated	
clinical	factors	and	outcome.	Critical	Care	Medicine.	2011;39((Chelazzi	C.;	Giugni	D.;	Villa	G.;	De	Gaudio	R.)	University	of	
Florence,	Italy):148.	
Rothstein	M,	Pereira	E,	Baker	S,	Arora	R,	Bhatkar	V,	Colombo	J.	Parasympathetic	involvement	in	sleep	medicine,	cardiovascular	
implications.	Clinical	Autonomic	Research.	2011;21(4):298.	
Ryodi	E,	Salmi	J,	Valimaki	M,	et	al.	Cardiovascular	morbidity	after	surgical	treatment	of	hyperthyroidism	-	A	nationwide	cohort	
study	with	a	long-term	follow-up.	Endocrine	Reviews.	2012;33(3).	
Selmer	C,	Olesen	J,	Lindhardsen	J,	et	al.	Subclinical	thyroid	disease	and	risk	of	new-onset	atrial	fibrillation.	Journal	of	the	American	
College	of	Cardiology.	2012;59(13):E662.	
Proenca	M,	Cardiga	R,	Araujo	I,	et	al.	Prognostic	value	of	subclinical	hyperthyroidism	in	an	internal	medicine	ward.	European	
Journal	of	Internal	Medicine.	2013;24((Proenca	M.;	Cardiga	R.;	Araujo	I.;	Marques	F.;	Jesus	S.;	Cardoso	D.;	Serra	S.;	Fonseca	
C.;	Leitao	A.;	Ceia	F.)	Medicine	III,	Sao	Francisco	Xavier	Hospital,	Lisbon,	Portugal):e102.	
Mueller	PS.	Thyroid	function	and	risk	for	AF:	A	linear	relation.	Medicine	Today.	2013;14(1):64.	
No	prospective	cohort	study	 Collet	T-H,	Gussekloo	J,	Bauer	DC,	et	al.	Subclinical	hyperthyroidism	and	the	risk	of	coronary	heart	disease	and	mortality.	Archives	
of	Internal	Medicine.	2012;172(10):799-809.	
Katircibasi	MT,	Deniz	F,	Pamukcu	B,	Binici	S,	Atar	I.	Effects	of	short-term	propylthiouracil	treatment	on	p	wave	duration	and	p	wave	
dispersion	in	patients	with	overt	hypertyroidism.	Experimental	&	Clinical	Endocrinology	&	Diabetes.	2007;115(6):376-379.	
Tanase	DM,	Ionescu	SD,	Ouatu	A,	Ambarus	V,	Arsenescu-Georgescu	C.	Risk	assessment	in	the	development	of	atrial	fibrillation	at	
patients	with	associate	thyroid	dysfunctions.	Revista	Medico-Chirurgicala	a	Societatii	de	Medici	Si	Naturalisti	Din	Iasi.	
2013;117(3):623-629.	
Tenerz	A,	Forberg	R,	Jansson	R.	Is	a	more	active	attitude	warranted	in	patients	with	subclinical	thyrotoxicosis?	Journal	of	Internal	
Medicine.	1990;228(3):229-233.	
Selmer	C,	Olesen	JB,	Hansen	ML,	et	al.	The	spectrum	of	thyroid	disease	and	risk	of	new	onset	atrial	fibrillation:	a	large	population	
cohort	study.	BMJ.	2012;345:e7895.	
Ruigomez	A,	Johansson	S,	Wallander	M-A,	Garcia	Rodriguez	LA.	Predictors	and	prognosis	of	paroxysmal	atrial	fibrillation	in	general	
practice	in	the	UK.	BMC	Cardiovascular	Disorders.	2005;5:20.	
Aras	D,	Maden	O,	Ozdemir	O,	et	al.	Simple	electrocardiographic	markers	for	the	prediction	of	paroxysmal	atrial	fibrillation	in	
hyperthyroidism.	International	Journal	of	Cardiology.	2005;99(1):59-64.	
Klein	Hesselink	EN,	Lefrandt	JD,	Schuurmans	EP,	et	al.	Increased	Risk	of	Atrial	Fibrillation	After	Treatment	for	Differentiated	Thyroid	
Carcinoma.	The	Journal	of	clinical	endocrinology	and	metabolism.	2015;	100(12):4563-9		
No	measurement	of	both	serum	
thyroid	stimulating	hormone	and	
thyroxine	at	baseline	
Geng	J,	Hu	T,	Wang	B,	Lu	W,	Ma	S.	Thyroid	stimulating	hormone	levels	and	risk	of	coronary	heart	disease	in	patients	with	type	2	
diabetes	mellitus.	International	Journal	of	Cardiology.	2014;174(3):851-853.	
Kim	E-J,	Lyass	A,	Wang	N,	et	al.	Relation	of	hypothyroidism	and	incident	atrial	fibrillation	(from	the	Framingham	Heart	Study).	
American	Heart	Journal.	2014;167(1):123-126.	
No	explicit	assessment	of	atrial	
fibrillation	outcome	events	
Trivalle	C,	Doucet	J,	Chassagne	P,	et	al.	Differences	in	the	signs	and	symptoms	of	hyperthyroidism	in	older	and	younger	patients.	
Journal	of	the	American	Geriatrics	Society.	1996;44(1):50-53.	
Kentsch	M,	Otter	W,	Kroger	B,	et	al.	[Bradycardia	despite	hyperthyroidism].	Zeitschrift	fur	Kardiologie.	2001;90(7):492-497.	
Nasim	A,	Shahzad	A,	Saeed	S.	Medium	term	effectiveness	of	thyroxine	treatment	in	congestive	cardiac	failure	(CCF).	Journal	of	
Postgraduate	Medical	Institute.	2009;23(2):124-134.	
Yonem	O,	Dokmetas	HS,	Aslan	SM,	Erselcan	T.	Is	antithyroid	treatment	really	relevant	for	young	patients	with	subclinical	
hyperthyroidism?	Endocrine	Journal.	2002;49(3):307-314.	
Azemi	T,	Bhavnani	S,	Kazi	F,	et	al.	Prognostic	impact	of	thyroid	stimulating	hormone	levels	in	patients	with	cardiomyopathy.	
Connecticut	Medicine.	2013;77(7):409-415.	
Auer	J,	Scheibner	P,	Mische	T,	Langsteger	W,	Eber	O,	Eber	B.	Subclinical	hyperthyroidism	as	a	risk	factor	for	atrial	fibrillation.	
American	Heart	Journal.	2001;142(5):838-842.	
Akdemir	R,	Ebru	Eryasar	N,	Celik	K,	et	al.	Increased	P	wave	dispersion	in	hypothyroidism:	A	sign	of	risk	of	atrial	fibrillation.	Turkish	
Journal	of	Medical	Sciences.	2009;39(4):629-633.	
Osman	F,	Franklyn	JA,	Daykin	J,	et	al.	Heart	rate	variability	and	turbulence	in	hyperthyroidism	before,	during,	and	after	treatment.	
American	Journal	of	Cardiology.	2004;94(4):465-469.	
Ceresini	G,	Marina	M,	Lauretani	F,	et	al.	Relationship	Between	Circulating	Thyroid-Stimulating	Hormone,	Free	Thyroxine,	and	Free	
Triiodothyronine	Concentrations	and	9-Year	Mortality	in	Euthyroid	Elderly	Adults.	Journal	of	the	American	Geriatrics	
Society.	2016;64(3):553-60.	
Studies	assessing	only	postoperative	
atrial	fibrillation	events	
Cerillo	AG,	Bevilacqua	S,	Storti	S,	et	al.	Free	triiodothyronine:	a	novel	predictor	of	postoperative	atrial	fibrillation.	European	Journal	
of	Cardio-Thoracic	Surgery.	2003;24(4):487-492.	
Kokkonen	L,	Majahalme	S,	Koobi	T,	et	al.	Atrial	fibrillation	in	elderly	patients	after	cardiac	surgery:	postoperative	hemodynamics	
and	low	postoperative	serum	triiodothyronine.	Journal	of	Cardiothoracic	&	Vascular	Anesthesia.	2005;19(2):182-187.	
Park	YJ,	Yoon	JW,	Kim	KI,	et	al.	Subclinical	hypothyroidism	might	increase	the	risk	of	transient	atrial	fibrillation	after	coronary	artery	
bypass	grafting.	Annals	of	Thoracic	Surgery.	2009;87(6):1846-1852.	
Guden	M,	Akpinar	B,	Saggbas	E,	Sanisoglu	I,	Cakali	E,	Bayindir	O.	Effects	of	intravenous	triiodothyronine	during	coronary	artery	
bypass	surgery.	Asian	Cardiovascular	&	Thoracic	Annals.	2002;10(3):219-222.	
Ozcan	S.	Relationship	between	atrial	fibrilation	and	coronary	bypass	surgery.	Pakistan	Journal	of	Medical	Sciences.	2014;30(3):630-
633.	
	
	
	
	 	
Supplemental	Table	3.	Baseline	Characteristics	of	Participants	by	Thyroid	Function	
Characteristic	
Euthyroidism	
(n=28,127)	
Subclinical	Hypothyroidism	
(n=1,958)	 p-value*	
Age	in	y,	mean	(SD)	 64.4	(13.5)	 69.9	(10.0)	 <0.001	
Women,	n	(%)	 14,285	(50.8)	 1,223	(62.5)	 <0.001	
Caucasian,	n	(%)	†	 18,095	(91.8)	 1,406	(91.8)	 0.92	
Body	mass	index	in	kg/m2,	mean	(SD)	‡	 26.6	(4.2)	 26.8	(4.3)	 0.072	
Thyroid	stimulating	hormone	in	mIU/L,	mean	(SD)	 1.81	(0.91)	 6.68	(2.59)	 <0.001	
Present	or	former	smoker,	n	(%)	 15,799	(56.2)	 980	(50.1)	 <0.001	
Systolic	blood	pressure	in	mmHg,	mean	(SD)	§	 139.2	(21.5)	 139.6	(22.4)	 0.36	
Total	cholesterol	in	mmol/l,	mean	(SD)	||		 6.08	(1.67)	 5.94	(1.38)	 <0.001	
Cardiovascular	disease,	n	(%)	 4,928	(17.5)	 443	(22.6)	 <0.001	
Heart	failure,	n	(%)	 655	(2.3)	 59	(3.0)	 0.054	
Stroke,	n	(%)	 624	(2.2)	 61	(3.1)	 0.010	
Diabetes,	n	(%)	 2,108	(7.5)	 196	(10.0)	 <0.001	
Antihypertensive	medication,	n	(%)	 10,593	(37.7)	 878	(44.8)	 <0.001	
Lipid-lowering	medication,	n	(%)	 3,772	(13.4)	 305	(15.6)	 0.007	
Amiodarone,	n	(%)	#	 101	(0.4)	 22	(1.1)	 <0.001	
Abbreviation:	SD,	standard	deviation.		
*p-values	were	derived	from	a	chi-squared	test	or	Student’s	t-test,	as	appropriate	
†	Information	on	race	was	missing	in	8,408	(29.9%)	participants	with	euthyroidism	and	427	(21.8%)	with	
subclinical	hypothyroidism	
‡	Information	on	body	mass	index	was	missing	in	128	(0.5%)	participants	with	euthyroidism	and	11	(0.6%)	with	
subclinical	hypothyroidism	
§	Information	on	systolic	blood	pressure	was	missing	in	79	participants	with	euthyroidism	(0.3%)	and	4	(0.2%)	
with	subclinical	hypothyroidism	
||	Information	on	total	cholesterol	was	missing	in	126	(0.4%)	participants	with	euthyroidism	and	7	(0.4%)	with	
subclinical	hypothyroidism	
#	Information	on	amiodarone	use	at	baseline	was	missing	in	all	participants	of	the	Busselton	Health	Study	
(1,023	participants	with	euthyroidism	and	37	with	subclinical	hypothyroidism)	
	Supplemental	Table	4.	Quality	Assessment	of	Included	Studies*	
Study		 Population	
studied	†	
Ascertainment	
of	exposure	‡		
Assessment	
of	AF	at	
baseline	
Controlling	for	additional	factors		 Methods	for	AF	ascertainment	 Duration	of	
follow-up,	
median	(IQR),	y	
Lost	to	
follow-
up	(%)		
United	States	 	 	 	 	 	 	 	
Cardiovascular	
Health	Study		
P,	4	
communities	
(USA)	
Third	
generation	TSH	
assay	
yes	 age	and	sex,	systolic	blood	pressure,	
current	or	former	smoking,	diabetes	
mellitus,	total	cholesterol,	and	prevalent	
cardiovascular	disease,	lipid	lowering	
medications,	antihypertensive	
medications,	BMI,	heart	rate,	and	
alcohol	consumption	
Self-report,	annual	ECG,	ICD-9	
hospital	discharge	codes	
	
11.7	(7.0-18.1)	 7.9-
10.1	
Health	ABC	
Study	
P,	2	cities	
(USA)	
Third	
generation	TSH	
assay	
yes	 age	and	sex,	systolic	blood	pressure,	
current	or	former	smoking,	diabetes	
mellitus,	total	cholesterol,	and	prevalent	
cardiovascular	disease,	lipid	lowering	
medications,	antihypertensive	
medications,	BMI,	heart	rate,	and	
alcohol	consumption	
Recoded	Minnesota	at	baseline	
and	year	4	follow-up	visits,	ICD-9	
coded	diagnoses	from	CMS	
(center	for	Medicare	and	
Medicaid)	data	
8.1	(7.4-8.3)	 <5	
Osteoporotic	
Fractures	in	
Men	(MrOS)	
Study	
P,	6	clinical	
centers	(USA)	
Third	
generation	TSH	
assay	
yes	 age	and	sex,	systolic	blood	pressure,	
current	or	former	smoking,	diabetes	
mellitus,	total	cholesterol,	and	prevalent	
cardiovascular	disease,	lipid	lowering	
medications,	antihypertensive	
medications,	BMI,	heart	rate,	and	
alcohol	consumption	
self	report	and	ECG	at	baseline,	
medical	records	and	supporting	
documentation	collected	every	
4months	(phone	or	postcard	
follow-up)	
12.6	(11.2-13.1)	 6		
Europe	 	 	 	 	 	 	 	
Bari	Study	 Outpatients	
with	
congestive	
heart	failure	
(Italy)	
Third	
generation	TSH	
assay	
yes	 age	and	sex,	systolic	blood	pressure,	
current	or	former	smoking,	diabetes	
mellitus,	total	cholesterol,	and	prevalent	
cardiovascular	disease,	lipid	lowering	
medications,	antihypertensive	
medications,	BMI		
ICD-9	at	discharge	 1.3	(0.6-1.9)	 <5	
Leiden	85+	
Study	
P,	1	town	
(Leiden,	The	
Netherlands)	
Third	
generation	TSH	
assay	
yes	 age	and	sex,	systolic	blood	pressure,	
current	or	former	smoking,	diabetes	
mellitus,	total	cholesterol,	and	prevalent	
cardiovascular	disease,	lipid	lowering	
medications,	antihypertensive	
medications,	BMI,	and	alcohol	
consumption	
Annual	ECG,	Minnesota	 5.5	(2.7-9.0)	 <5	
Study	of	
Health	in	
Pomerania	
P,	1	region	
(West	
Pomerania,	
Germany)	
Third	
generation	TSH	
assay	
yes	 age	and	sex,	systolic	blood	pressure,	
current	or	former	smoking,	diabetes	
mellitus,	total	cholesterol,	and	prevalent	
cardiovascular	disease,	lipid	lowering	
medications,	antihypertensive	
medications,	BMI,	heart	rate	
Minnesota	at	baseline	+	year	5	
follow-up	and	ongoing	year	10	
follow-up	
11.5	(11.1-12.1)	 37	
Invecchiare	in	
Chianti	Study	
P,	2	towns	in	
Toscany	(Italy)	
Third	
generation	TSH	
assay	
yes	 age	and	sex,	systolic	blood	pressure,	
current	or	former	smoking,	diabetes	
mellitus,	total	cholesterol,	and	prevalent	
cardiovascular	disease,	lipid	lowering	
medications,	antihypertensive	
medications,	BMI,	heart	rate,	and	
alcohol	consumption	
ECG	at	baseline	and	year	3	
follow-up,	year	6	follow-up	and	
year	9	follow-up	
9.0	(8.3-9.2)	 35	
Rotterdam	
Study	
P,	1	district	
(The	
Netherlands)	
Third	
generation	TSH	
assay	
yes	 age	and	sex,	systolic	blood	pressure,	
current	or	former	smoking,	diabetes	
mellitus,	total	cholesterol,	and	prevalent	
cardiovascular	disease,	lipid	lowering	
medications,	antihypertensive	
medications,	BMI,	heart	rate,	and	
alcohol	consumption	
i)	12	lead	ECG	at	baseline	and	
follow-up	visits	ii)	ICD-10	coded	
info	from	GPs	(own	records,	
hospital	discharge	letters)	with	
requirement	of	ECG	verifying	the	
diagnosis	iii)	hospital	discharge	
diagnoses	through	Dutch	
National	Medical	Registration	
15.5	(11.4-16.9)	 0.9	
PROSPER	
Study	
Primary	care	
patients,	in	3	
countries	(The	
Netherlands,	
Ireland,	
Scotland)	
Third	
generation	TSH	
assay	
yes	 age	and	sex,	systolic	blood	pressure,	
current	or	former	smoking,	diabetes	
mellitus,	total	cholesterol,	and	prevalent	
cardiovascular	disease,	lipid	lowering	
medications,	antihypertensive	
medications,	BMI,	heart	rate,	and	
alcohol	consumption	
Annual	single-lead	ECG	or	12-lead	
ECG	or	telemetry	during	
hospitalization	or	other	clinical	
care	
3.3	(3.0-3.5)	 <5	
EPIC-Norfolk	 P,	1	county	
(Norfolk,	
England)	
Third	
generation	TSH	
assay	
yes	 age	and	sex,	systolic	blood	pressure,	
current	or	former	smoking,	diabetes	
mellitus,	total	cholesterol,	and	prevalent	
cardiovascular	disease,	lipid	lowering	
medications,	antihypertensive	
medications,	BMI,	heart	rate,	and	
alcohol	consumption	
Baseline:	self-reported	intake	of	
drugs	used	for	AF	treatment:	
digitalis	and	vitamin	K	
antagonists.	Incident	AF:	ICD-10	
coded	hospital	discharge	codes		
17.0	(16.1-18.0)	 <2	
Australia	 	 	 	 	 	 	 	
Busselton	
Health	Study	
P,	1	district	
(Busselton,	
Australia)	
Third	
generation	TSH	
assay	
yes	 age	and	sex,	systolic	blood	pressure,	
current	or	former	smoking,	diabetes	
mellitus,	total	cholesterol,	and	prevalent	
cardiovascular	disease,	antihypertensive	
medications,	BMI	
ECG	at	baseline	and	year	14	
follow-up	
14.0	(14.0-14.0)	 37	
	
Abbreviations:	AF,	atrial	fibrillation;	BMI,	body	mass	index;	ECG,	electrocardiogram;	GP,	general	practitioner;	NR,	not	reported;	P,	population-based	study.		
*If	an	article	did	not	clearly	mention	one	of	these	characteristics,	we	considered	that	is	had	not	been	done.	All	included	studies	were	prospective	cohort	studies.	
†	A	population-based	study	was	defined	as	a	random	sample	of	the	general	population.		
‡	A	formal	adjudication	procedure	was	defined	as	having	clear	criteria	for	the	outcome	that	were	reviewed	by	experts	for	each	potential	case.	
	
	
	
	
	
	
	
	
Supplemental	Table	5.	Sensitivity	Analyses	of	the	Association	between	Thyroid	Stimulating	Hormone	within	the	Reference	Range	and	the	Risk	of	Atrial	Fibrillation	
TSH	level	(mlU/l)	 0.45-0.99	 	 1.00-1.49	 	 1.50-2.49	 	 2.50-3.49	 	 3.50-4.49	 	
	 Events	/	Persons	
HR	
(95%	CI)	
Events	/	
Persons	
HR	
(95%	CI)	
Events	/	
Persons	
HR	
(95%	CI)	
Events	/	
Persons	
HR	
(95%	CI)	
Events	/	
Persons	
HR	
(95%	CI)	
Main	analysis		
(age-	and	sex-adjusted)	 372/5665	
1.10	
(0.92-1.31)	 492/6275	
1.03	
(0.87-1.22)	 893/9990	
1.04	
(0.89-1.22)	 412/4391	
0.94	
(0.79-1.12)	 190/1806	 ref.	
Excluding	users	of	amiodarone	and	
a	study	with	missing	relevant	data*		 365/5369	
1.09	
(0.91-1.30)	 485/5956	
1.02	
(0.86-1.21)	 883/9622	
1.03	
(0.88-1.21)	 408/4293	
0.93	
(0.78-1.11)	 190/1763	 ref.	
Excluding	thyroid	medication	use		
at	BL	and/or	FUP	and	studies	with	
missing	relevant	data	†	
225/3510	 1.05	(0.84-1.32)	 306/3286	
1.01	
(0.82-1.25)	 596/4994	
1.06	
(0.88-1.29)	 292/2412	
0.96	
(0.78-1.18)	 124/945	 ref.	
Abbreviations:	BL,	baseline;	CI,	confidence	interval;	FUP,	follow-up;	HR,	hazard	ratio;	TSH,	thyroid	stimulating	hormone.	
*	A	total	of	1,183	participants	were	excluded	for	this	sensitivity	analysis	of	the	association	between	TSH	and	atrial	fibrillation:	2	participants	who	took	amiodarone	in	the	
Cardiovascular	Health	Study;	3	in	the	Health	ABC	Study;	1	in	the	Osteoporotic	Fractures	in	Men	Study;	79	in	the	Bari	Study;	1	in	the	Leiden	85+	Study;	1	in	the	Study	of	Health	in	
Pomerania;	6	in	the	Invecchiare	in	Chianti	Study;	6	in	the	Rotterdam	Study;	23	in	the	PROSPER	Study;	1	in	the	EPIC-Norfolk	Study,	and	all	1,060	participants	from	the	Busselton	
Health	Study,	in	which	information	on	amiodarone	use	was	not	available.	
†	The	number	of	thyroid	medication	users	during	follow-up	are	indicated	in	Table	1.	We	additionally	excluded	11,642	participants	in	the	EPIC-Norfolk	Study	and	1,607	in	the	
Rotterdam	Study	from	this	sensitivity	analysis	on	the	association	between	TSH	and	atrial	fibrillation,	because	information	on	thyroid	medication	use	during	follow-up	was	not	
available	in	these	studies.		
	
	 	
Supplemental	Table	6.	Stratified	Analyses	for	the	Association	between	Thyroid	Stimulating	Hormone	within	the	Reference	Range	and	Atrial	Fibrillation*	
TSH	level	(mlU/l)	 0.45-0.99	 	 	 1.00-1.49	 	 	 1.50-2.49	 	 	 2.50-3.49	 	 	 3.50-4.49	
Variable	 Events/		Persons	
HR	
(95%	CI)	
HR	
(95%CI)	
Events/		
Persons	
HR	
(95%	CI)	
HR	
(95%	CI)	
Events/		
Persons	
HR	
(95%	CI)	
HR	
(95%	CI)	
Events/		
Persons	
HR	
(95%	CI)	
HR	
(95%	CI)	
Events/		
Persons	
	 	 Age/Sex	Adj	 Multivariate	Model	§	
	 Age/Sex	Adj	 Multivariate	Model	‡	
	 Age/Sex	Adj	 Multivariate	Model	‡	
	 Age/Sex	Adj	 Multivariate	Model	‡	
	
Total	
Population	 372/5665	
1.10		
(0.92-1.31)	
1.07	
(0.89-1.28)	 492/6275	
1.03	
(0.87-1.22)	
0.99	
(0.84-1.18)	 893/9990	
1.04	
(0.89-1.22)	
1.02	
(0.87-1.19)	 412/4391	
0.94	
(0.79-1.12)	
0.92	
(0.78-1.10)	 190/1806	
Age,	y	 	 	 	 	 	 	 	 	 	 	 	 	 	
18-64	 59/3051	 0.82	(0.48-1.42)	
0.86	
(0.50-1.47)	 67/2760	
0.83	
(0.49-1.41)	
0.87	
(0.51-1.47)	 102/3935	
0.81	
(0.49-1.33)	
0.78	
(0.47-1.30)	 34/1367	
0.81	
(0.46-1.44)	
0.78	
(0.44-1.37)	 18/563	
≥65	 313/2614	 1.06	(0.88-1.28)	
1.04	
(0.86-1.25)	 425/3515	
0.97	
(0.82-1.16)	
0.94	
(0.79-1.13)	 791/6055	
1.03	
(0.87-1.21)	
1.01	
(0.85-1.19)	 378/3024	
0.92	
(0.77-1.11)	
0.91	
(0.76-1.09)	 172/1243	
P	for	Trend	 	 0.97	 0.97	 	 0.97	 0.97	 	 0.97	 0.97	 	 0.97	 0.97	 	
Sex	 	 	 	 	 	 	 	 	 	 	 	 	 	
Women	 160/2791	 1.03		(0.80-1.32)	
1.00		
(0.78	-1.28)	 210/3079	
0.97		
(0.76-1.22)	
0.93	
	(0.74-1.18)	 408/4967	
1.02		
(0.82-1.26)	
1.00	
(0.80-	1.24)	 202/2352	
0.93		
(0.74-1.18)	
0.91	
	(0.72-1.16)	 107/1096	
Men	 212/2874	 1.16		(0.89-1.50)	
1.13		
(0.87-1.47)	 282/3196	
1.11		
(0.87-1.42)	
1.07		
(0.83-1.37)	 485/5023	
1.09		
(0.86	to	1.38)	
1.06		
(0.84-1.35)	 210/2039	
0.97		
(0.75-1.25)	
0.95	
	(0.73-1.23)	 83/710	
P	for	Interaction	 	 0.64	 0.81	 	 0.64	 0.81	 	 0.64	 0.81	 	 0.64	 0.81	 	
Race	†	 	 	 	 	 	 	 	 	 	 	 	 	 	
White	 247/2763	 1.19	(0.97-1.46)	
1.17	
(0.95-1.44)	 332/4059	
1.00	
(0.83-1.22)	
0.96	
(0.79-1.17)	 619/6922	
1.01	
(0.84-1.20)	
0.97	
(0.81-1.17)	 292/3038	
0.90	
(0.74-1.09)	
0.87	
(0.72-1.06)	 153/1313	
Non-white	 23/268	 0.95	(0.42-2.12)	
0.92	
(0.41-2.07)	 47/381	
1.48	
(0.70-3.13)	
1.38	
(0.65-2.93)	 68/610	
1.40	
(0.67-2.91)	
1.34		
(0.64-2.80)	 35/264	
1.63	
(0.75-3.51)	
1.51	
(0.70-3.27)	 8/101	
P	for	Interaction	 	 0.037	 0.033	 	 0.037	 0.033	 	 0.037	 0.033	 	 0.037	 0.033	 	
Previous	CVD	 	 	 	 	 	 	 	 	 	 	 	 	 	
None	‡	 263/4876	 1.15	(0.93-1.42)	
1.14	
(0.92-1.41)	 349/5196	
1.10	
(0.90-1.34)	
1.08	
(0.88-1.32)	 616/8186	
1.07	
(0.89-1.29)	
1.05	
(0.87-1.28)	 278/3471	
0.96	
(0.78-1.18)	
0.96	
(0.78-1.19)	 132/1470	
Yes	 109/789	 0.91	(0.66-1.26)	
0.91	
(0.66-1.26)	 143/1079	
0.82	
(0.61-1.12)	
0.81	
(0.60-1.10)	 277/1804	
0.92	
(0.70-1.23)	
0.93	
(0.70-1.24)	 134/920	
0.84	
(0.62-1.14)	
0.83	
(0.60-1.13)	 58/336	
P	for	Interaction	 	 0.78	 0.74	 	 0.78	 0.74	 	 0.78	 0.74	 	 0.78	 0.74	 	
Thyroxine	use	at	
BL	
	 	 	 	 	 	 	 	 	 	 	 	 	
None	 372/5665	 1.10	(0.92-1.31)	
1.07	
(0.89-1.28)	 492/6275	
1.03	
(0.87-1.22)	
0.99	
(0.84-1.18)	 893/9990	
1.04	
(0.89-1.22)	
1.02	
(0.87-1.19)	 412/4391	
0.94	
(0.79-1.12)	
0.92	
(0.78-1.10)	 190/1806	
Yes	 27/244	 1.28	(0.62-2.66)	
1.45	
(0.68-3.10)	 22/154	
1.57	
(0.74-3.33)	
1.65	
(0.76-3.60)	 32/233	
1.52	
(0.74-3.10)	
1.60	
(0.76-3.37)	 19/139	
1.42	
(0.66-3.07)	
1.52	
(0.68-3.39)	 10/105	
P	for	Interaction	 	 0.37	 0.31	 	 0.37	 0.31	 	 0.37	 0.31	 	 0.37	 0.31	 	
Abbreviations:	Adj,	adjusted;	AF,	atrial	fibrillation;	BL,	baseline;	CI,	confidence	interval;	CVD,	cardiovascular	disease;	E,	events;	HR,	hazard	ratio;	NA,	data	not	applicable;	P,	
participants;	TSH,	thyroid-stimulating	hormone	
*	The	TSH	category	3.50-4.49mIU/l	was	the	reference	category	
†	African	Americans,	Hispanics,	Asian,	and	others	were	considered	as	non-white	population.	Data	on	race	were	missing	for	all	participants	of	the	SHIP	study,	the	InChianti	
Study,	and	the	PROSPER	Study,	67	participants	of	the	Rotterdam	Study	and	44	of	the	EPIC-Norfolk	Study.	
‡	Previous	cardiovascular	was	defined	as	a	history	of	stroke,	transient	ischemic	attack,	myocardial	infarction,	angina	pectoris,	coronary	angioplasty,	bypass	surgery.	Participants	
without	any	of	these	events	were	considered	having	no	previous	cardiovascular	disease.	
§	Adjusted	for	age,	sex,	systolic	blood	pressure,	current	and	former	smoking,	diabetes,	total	cholesterol	and	prevalent	cardiovascular	disease.	
	
	 	
Supplemental	Table	7.	Sensitivity	Analyses	of	the	Association	between	Subclinical	Hypothyroidism	and	the	Risk	of	Atrial	Fibrillation	
TSH	level	(mlU/l)	 3.50-4.49	 	 4.5-6.9	 	 7.0-9.9	 	 10.0-19.9	 	
	 Events	/	Participants	
HR	
(95%	CI)	
Events	/	
Participants	
HR	
(95%	CI)	
Events	/	
Participants	
HR	
(95%	CI)	
Events	/	
Participants	
HR	
(95%	CI)	
Main	analysis		
(age-	and	sex-adjusted)	 190/1806		 ref.	 149/1384	
0.92	
(0.74-1.14)	 44/383	
1.02	
(0.73-1.41)	 22/191	
0.94	
(0.61-1.47)	
Excluding	users	of	amiodarone	and	a	
study	with	missing	relevant	data*		 190/1763	 ref.	 146/1355	
0.90	
(0.73-1.12)	 43/371	
1.00	
(0.72-1.39)	 20/173	
0.90	
(0.57-1.42)	
Excluding	thyroid	medication	use		
at	BL	and/or	FUP	and	studies	with	
missing	relevant	data	†	
124/945	 ref.	 81/719	 0.87	(0.66-1.16)	 22/147	
1.22	
(0.78-1.92)	 11/60	
1.56	
(0.84-2.90)	
Abbreviations:	BL,	baseline;	CI,	confidence	interval;	FUP,	follow-up;	HR,	hazard	ratio;	TSH,	thyroid	stimulating	hormone.	
*	Information	on	amiodarone	use	at	baseline	was	not	available	in	the	Busselton	Health	Study.	
†	The	number	of	thyroid	medication	users	during	follow-up	are	indicated	in	Table	1.	We	additionally	excluded	participants	in	the	EPIC-Norfolk	Study	and	the	Rotterdam	Study,	
because	information	on	thyroid	medication	use	during	follow-up	was	not	available	in	these	studies.		
	
	 	
Supplemental	Table	8.	Stratified	Analyses	for	the	Association	between	Subclinical	Hypothyroidism	and	Atrial	Fibrillation*	
TSH	level	(mlU/l)	 3.50-4.49	 4.5-6.9	 	 	 7.0-9.9	 	 	 10.0-19.9	 	 	
Variable	 Events/		Persons	
Events/		
Persons	
HR	
(95%	CI)	
HR	
(95%CI)	
Events/		
Persons	
HR	
(95%	CI)	
HR	
(95%	CI)	
Events/		
Persons	
HR	
(95%	CI)	
HR	
(95%	CI)	
	 	 	 Age/Sex	Adj	 Multivariate	Model	§	
	 Age/Sex	Adj	 Multivariate	Model	‡	
	 Age/Sex	Adj	 Multivariate	Model	‡	
Total	
Population	 190/1806	 149/1384	
0.92	
(0.74-1.14)	
0.91	
(0.74-1.14)	 44/383	
1.02	
(0.73-1.41)	
0.95	
(0.68-1.33)	 22/191	
0.94	
(0.61-1.47)	
0.93	
(0.60-1.44)	
Age	 	 	 	 	 	 	 	 	 	 	
18-64	 18/563	 7/339	 0.69	(0.29-1.64)	
0.67	
(0.28-1.60)	 2/91	
0.72	
(0.17-3.09)	
0.79	
(0.18-3.40)	 1/51	
0.66	
(0.09-4.95)	
0.76	
(0.10-5.70)	
≥65	 172/1243	 142/1045	 0.95	(0.76-1.19)	
0.96		
(0.76-1.19)	 42/292	
1.02	
(0.72-1.42)	
0.96	
(0.68-1.34)	 21/140	
1.05	
(0.67-1.65)	
1.03	
(0.65-1.62)	
P	for	Trend	 	 	 0.97	 0.97	 	 0.97	 0.97	 	 0.97	 0.97	
Sex	 	 	 	 	 	 	 	 	 	 	
Women	 107/1096	 75/853	 0.79	(0.59-1.06)	
0.80	
(0.60-1.08)	 25/249	
0.96	
(0.62-1.48)	
0.90	
(0.58-1.40)	 10/121	
0.71	
(0.37-1.37)	
0.73	
(0.38-1.39)	
Men	 83/710	 74/531	 1.11	(0.81-1.52)	
1.07	
(0.78-1.47)	 19/134	
1.10	
(0.67-1.81)	
1.01	
(0.60-1.68)	 12/70	
1.27	
(0.69-2.34)	
1.21	
(0.66-2.22)	
P	for	Interaction	 	 	 0.64	 0.81	 	 0.64	 0.81	 	 0.64	 0.81	
Race	†	 	 	 	 	 	 	 	 	 	 	
White	 153/1313	 133/989	 1.03	(0.82-1.30)	
1.01	
(0.80-1.28)	 39/278	
1.14	
(0.80-1.62)	
1.05	
(0.73-1.50)	 18/139	
0.94	
(0.58-1.54)	
0.93	
(0.57-1.52)	
Non-white	 8/101	 5/90	 0.58	(0.19-1.78)	
0.54	
(0.17-1.64)	 1/25	
0.41	
(0.05-3.25)	
0.38	
(0.05-3.07)	 0/10	 NA	 NA	
P	for	Interaction	 	 	 0.037	 0.033	 	 0.037	 0.033	 	 0.037	 0.033	
Previous	CVD	 	 	 	 	 	 	 	 	 	 	
None		‡	 132/1470	 100/1078	 0.97	(0.75-1.26)	
0.99	
(0.76-1.29)	 28/291	
0.98	
(0.65-1.48)	
0.93	
(0.61-1.41)	 16/146	
1.11	
(0.66-1.87)	
1.13	
(0.67-1.90)	
Yes	 58/336	 49/306	 0.76	(0.52-1.11)	
0.77	
(0.53-1.14)	 16/92	
1.00	
(0.58-1.74)	
0.99	
(0.57-1.73)	 6/45	
0.65	
(0.28-1.52)	
0.67	
(0.29-1.55)	
P	for	Interaction	 	 	 0.78	 0.74	 	 0.78	 0.74	 	 0.78	 0.74	
Thyroxine	use	at	BL	 	 	 	 	 	 	 	 	 	 	
None	 190/1806	 149/1384	 0.92	(0.74-1.14)	
0.91	
(0.74-1.14)	 44/383	
1.02	
(0.73-1.41)	
0.95	
(0.68-1.33)	 22/191	
0.94	
(0.61-1.47)	
0.93	
(0.60-1.45)	
Yes	 10/105	 13/135	 0.98	(0.43-2.24)	
0.95	
(0.40-2.26)	 3/73	
0.45	
(0.12-1.63)	
0.53	
(0.14-1.95)	 11/63	
1.87	
(0.79-4.41)	
1.95	
(0.81-4.74)	
P	for	Interaction	 	 	 0.37	 0.31	 	 0.37	 0.31	 	 0.37	 0.31	
	
Abbreviations:	AF,	atrial	fibrillation;	BL,	baseline;	CI,	confidence	interval;	CVD,	cardiovascular	disease;	E,	events;	HR,	hazard	ratio;		
NA,	data	not	applicable;	P,	participants;	TSH,	thyroid-stimulating	hormone	
*	The	TSH	category	3.50-4.49mIU/l	was	the	reference	category	
†	African	Americans,	Hispanics,	Asian,	and	others	were	considered	as	non-white	population.	Data	on	race	were	missing	for	all	participants	of	the	SHIP	study,	the	InChianti	
Study,	and	the	PROSPER	Study,	67	participants	of	the	Rotterdam	Study	and	44	of	the	EPIC-Norfolk	Study.	
‡	Previous	cardiovascular	was	defined	as	a	history	of	stroke,	transient	ischemic	attack,	myocardial	infarction,	angina	pectoris,	coronary	angioplasty,	bypass	surgery.	Participants	
without	any	of	these	events	were	considered	having	no	previous	cardiovascular	disease.	
§	Adjusted	for	age,	sex,	systolic	blood	pressure,	current	and	former	smoking,	diabetes,	total	cholesterol	and	prevalent	cardiovascular	disease.	
	
	
	 	
Supplemental	Table	9.	Sensitivity	Analyses	of	the	Association	between	Quartiles	of	Free	Thyroxine	within	the	Reference	Range	and	the	Risk	of	Atrial	Fibrillation	
fT4	quartile	 First	quartile	 	
Second	
quartile	 	
Third	
quartile	 	
Fourth	
quartile	
	 	
	 Events	/	Participants	
HR	
(95%	CI)	
Events	/	
Participants	
HR	
(95%	CI)	
Events	/	
Participants	
HR	
(95%	CI)	
Events	/	
Participants	
HR	
(95%	CI)	
P	for	
trend	
Main	analysis		
(age-	and	sex-adjusted)	 371/5642	 ref.	 390/4989	
1.17	
(1.02-1.35)	 438/5272	
1.25	
(1.09-1.43)	 474/5018	
1.45	
(1.26-1.66)	 £0.001	
Excluding	users	of	amiodarone	and	a	
study	with	missing	relevant	data	*	 367/5245	 ref.	 389/4817	
1.17	
(1.02-1.35)	 433/5000	
1.24	
(1.08-1.42)	 463/4793	
1.42	
(1.24-1.63)	 £0.001	
Excluding	thyroid	medication	use		
at	BL	and/or	FUP	and	studies	with	
missing	relevant	data	†	
211/2345	 Ref.	 238/2063	 1.17	(0.97-1.40)	 218/2115	
1.16	
(0.96-1.40)	 250/2063	
1.37	
(1.14-1.64)	 0.002	
Abbreviations:	BL,	baseline;	CI,	confidence	interval;	fT4;	free	thyroxine;	FUP,	follow-up;	HR,	hazard	ratio.	
*	A	total	of	1,066	participants	were	excluded	for	this	sensitivity	analysis	of	the	association	between	fT4	and	atrial	fibrillation:	1	participant	who	took	amiodarone	in	the	CHS;	1	
in	the	MrOS;	57	in	the	Bari	Study;	3	in	the	InChianti	Study;	1	in	the	EPIC-Norfolk	Study,	and	all	1003	participants	in	the	Busselton	Health	Study,	in	which	information	on	
amiodarone	use	was	not	available.	
†	A	total	of	12,335	participants	were	excluded	for	this	sensitivity	analysis	of	the	association	between	fT4	and	atrial	fibrillation:	139	participants	in	the	CHS;	11	in	the	MrOS;	15	in	
the	Bari	Study;	3	in	the	Leiden	85+	Study;	156	in	the	SHIP;	13	in	the	InChianti	Study;	2	in	the	PROSPER	Study;	and	9	in	the	Busselton	Health	Study;	and	all	10,745	participants	in	
the	EPIC-Norfolk	Study	and	all	1,242	participants	in	the	Rotterdam	Study,	because	information	on	thyroid	medication	use	during	follow-up	was	not	available	in	these	studies.		
	 	
Supplemental	Table	10.	Stratified	Analyses	for	the	Association	between	Quartiles	of	Free	Thyroxine	within	the	Reference	Range	and	the	Risk	of	Atrial	Fibrillation	*	
fT4	Quantile	 First	
Quartile	
	 	 Second	
Quartile	
	 	 Third	
Quartile	
	 	 Fourth	
Quartile	
	 	
Variable	 Events/		Persons	
HR	
(95%	CI)	
HR	
(95%CI)	
Events/		
Persons	
HR	
(95%	CI)	
HR	
(95%	CI)	
Events/		
Persons	
HR	
(95%	CI)	
HR	
(95%	CI)	
Events/		
Persons	
HR	
(95%	CI)	
HR	
(95%	CI)	
	 	 Age/Sex	Adj	 Multivariate	Model	§	
	 Age/Sex	Adj	 Multivariate	Model	§	
	 Age/Sex	Adj	 Multivariate	Model	§	
	 Age/Sex	Adj	 Multivariate	Model	§	
Total	
Population	 371/5642	 ref.	 ref.	 390/4989	
1.17	
(1.02-1.35)	
1.16	
(1.00-1.33)	 438/5272	
1.25	
(1.09-1.43)	
1.19	
(1.04-1.37)	 474/5018	
1.45	
(1.26-1.66)	
1.39	
(1.22-1.60)	
Age,	y	 	 	 	 	 	 	 	 	 	 	 	 	
18-64	 62/3146	 ref.	 ref.	 47/2704	 0.85	(0.58-1.24)	
0.85	
(0.58-1.24)	 73/2818	
1.26	
(0.90-1.77)	
1.25	
(0.89-1.76)	 81/2561	
1.54	
(1.10-2.14)	
1.53	
(1.09-2.14)	
≥65	 309/2496	 ref.	 ref.	 343/2285	 1.23	(1.05-1.43)	
1.20	
(1.03-1.40)	 365/2454	
1.23	
(1.06-1.43)	
1.17	
(1.00-1.37)	 393/2457	
1.46	
(1.25-1.69)	
1.39	
(1.20-1.62)	
P	for	Trend	 	 	 	 	 0.16	 0.15	 	 0.16	 0.15	 	 0.16	 0.15	
Sex	 	 	 	 	 	 	 	 	 	 	 	 	
Women	 170/3123	 ref.	 ref.	 169/2596	 1.13	(0.91-1.39)	
1.12	
(0.90-1.39)	 215/2700	
1.41		
(1.15-1.72)	
1.33	
(1.09-1.64)	 214/2269	
1.56	
(1.27-1.90)	
1.51	
(1.23-1.85)	
Men	 201/2519	 ref.	 ref.	 221/2393	 1.20	(0.99-1.46)	
1.18	
(0.97-1.43)	 223/2572	
1.12	
(0.93-1.36)	
1.07	
(0.88-1.30)	 260/2749	
1.36	
(1.13-1.64)	
1.30	
(1.08-1.56)	
P	for	Interaction	 	 	 	 	 0.16	 0.18	 	 0.16	 0.18	 	 0.16	 0.18	
Race	†	 	 	 	 	 	 	 	 	 	 	 	 	
White	 311/4405	 ref.	 ref.	 333/3848	 1.17	(1.00-1.36)	
1.16	
(0.99-1.35)	 383/4072	
1.29	
(1.11-1.50)	
1.23	
(1.06-1.44)	 414/3876	
1.48	
(1.28-1.71)	
1.41	
(1.22-1.64)	
Non-white	 27/208	 ref.	 ref.	 27/141	 1.42	(0.83-2.43)	
1.46	
(0.84-2.53)	 32/179	
1.36	
(0.81-2.27)	
1.43	
(0.85-2.42)	 30/172	
1.61	
(0.96-2.72)	
1.77	
(1.04-3.01)	
P	for	Interaction	 	 	 	 	 0.93	 0.98	 	 0.93	 0.98	 	 0.93	 0.98	
Previous	CVD		 	 	 	 	 	 	 	 	 	 	 	 	
None	‡	 267/5089	 ref.	 ref.	 288/4449	 1.20	(1.02-1.42)	
1.17	
(0.99-1.39)	 324/4670	
1.32	
(1.12-1.55)	
1.26	
(1.07-1.49)	 362/4394	
1.57	
(1.34-1.84)	
1.52	
(1.29-1.78)	
Yes	 104/553	 ref.	 ref.	 102/540	 1.06	(0.80-1.39)	
1.07	
(0.81-1.41)	 114/602	
1.01	
(0.77-1.32)	
1.01	
(0.77-1.32)	 112/624	
1.05	
(0.81-1.38)	
1.05	
(0.80-1.37)	
P	for	Interaction	 	 	 	 	 0.068	 0.084	 	 0.068	 0.084	 	 0.068	 0.084	
Thyroxine	use	at	
BL	 	 	 	 	 	 	 	 	 	 	 	 	
None	 371/5655	 ref.	 ref.	 414/5122	 1.16	(1.01-1.34)	
1.15	
(1.00-1.32)	 431/5335	
1.28	
(1.11-1.47)	
1.22	
(1.06-1.41)	 457/4809	
1.43	
(1.25-1.64)	
1.38	
(1.20-1.59)	
Yes	||	 9/69	 ref.	 ref.	 13/78	 1.69	(0.70-4-05)	
1.66	
(0.69-3.98)	 16/120	
1.59	
(0.68-3.70)	
1.68	
(0.72-3.95)	 30/275	
1.41	
(0.65-3.08)	
1.48	
(0.67-3.26)	
P	for	Interaction	 	 	 	 	 0.53	 0.58	 	 0.53	 0.58	 	 0.53	 0.58	
Abbreviations:	Adj,	adjusted;	AF,	atrial	fibrillation;	BL,	baseline;	CI,	confidence	interval;	CVD,	cardiovascular	disease;	E,	events;	HR,	hazard	ratio;	NA,	data	not	applicable;	P,	
participants;	ref.,	reference;	TSH,	thyroid-stimulating	hormone	
*	This	analysis	was	restricted	to	normal	thyroid	function,	i.e.	TSH	and	thyroxine	in	the	reference	range.	From	the	overall	sample	a	total	of	9164	participants	were	excluded	for	
this	analysis	with	either	missing	measurements	of	fT4	or	thyroid	function	outside	the	reference	range.	479	participants	of	the	Cardiovascular	Health	Study,	59	of	the	
Osteoporotic	Fractures	in	Men	Study,	32	of	the	Bari	Study,	137	of	the	Leiden	85+	Study,	125	of	the	Study	of	Health	in	Pomerania,	42	of	the	InChianti	Study,	365	of	the	
Rotterdam	Study,	897	of	the	EPIC-Norfolk	Study,	and	57	of	the	Busselton	Health	Study.	In	participants	of	the	Health	ABC	Study,	fT4	was	measured	only	in	TSH	³	7.0	mIU/L;	
therefore	all	2346	participants	were	excluded	for	this	analysis.	In	the	PROSPER	Study,	fT4	was	measured	only	in	participants	with	TSH	<0.45mIU/l	or	TSH	³4.5mIU/l;	therefore,	
4625	participants	were	excluded	from	this	analysis.	
†	African	Americans,	Hispanics,	Asian,	and	others	were	considered	as	non-white	population.	Data	on	race	were	missing	for	all	participants	of	the	SHIP	study,	the	InChianti	
Study,	and	the	PROSPER	Study,	51	participants	of	the	Rotterdam	Study	and	37	of	the	EPIC-Norfolk	Study.	
‡	Previous	cardiovascular	was	defined	as	a	history	of	stroke,	transient	ischemic	attack,	myocardial	infarction,	angina	pectoris,	coronary	angioplasty,	bypass	surgery.	Participants	
without	any	of	these	events	were	considered	having	no	previous	cardiovascular	disease.	
§	Adjusted	for	age,	sex,	systolic	blood	pressure,	current	and	former	smoking,	diabetes,	total	cholesterol	and	prevalent	cardiovascular	disease.	
||	542	participants	with	available	measurement	of	fT4	and	normal	thyroid	function	were	on	thyroxine	at	baseline:	167	participants	of	the	CHS,	33	of	the	MrO2,	6	of	the	Bari,	5	
of	the	Leiden	85+	Study,	76	of	SHIP,	11	of	the	InChianti	Study,	9	of	the	Rotterdam	Study,	8	of	the	PROSPER	Study,	224	of	the	EPIC-Norfolk	Study,	and	3	of	the	Busselton	Health	
Study.	
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Participants	with	euthyroidism	or	
subclinical	hypothyroidism	and	available	
data	on	AF	outcomes	and	no	AF	at	
baseline		
(n	=	31,262)	
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dysfunction:	
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Overt	hyperthyroidism	(n	=	368)	
Exclude	participants	with	subclinical	
hyperthyroidism	(n	=	2,023)	
Participants	with	euthyroidism	or	
subclinical	thyroid	dysfunction	
(n	=	36,278)	
Participants	with	available	TSH	
measurements									
(n	=	37,151)	
	
Exclude	participants	with:	
Both	TSH	and	fT4	below	normal	range	(n	=	47)	
Both	TSH	and	fT4	above	normal	range	(n	=	20)	
Exclude	participants	with	prevalent	AF	at	
baseline	(n	=	1,397)	
Exclude	participants	with	missing	data	on	
incident	AF	outcomes	(n	=	1,596)	
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analysis	
participants	with	euthyroidism	or	
subclinical	hypothyroidism,	without	
thyroid	medication	at	baseline,	without	
AF	at	baseline,	with	available	data	on	AF	
outcomes	
(n	=	30,085)	
Exclude	participants	with	thyroxine	or	anti-
thyroid	medication	at	baseline	(n	=	1,177)	
Participants	with	euthyroidism	or	
subclinical	hypothyroidism	
(n	=	34,255)	
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Records	identified	through	
database	searching*	
(n	=	1418)	
Additional	record	identified	
through	other	sources	†	
(n=8)		
Records	screened	(n	=	1400)		
Studies	for	which	IPD	were	sought								
(n	=	13)	
Records	excluded	based	on	title	and	abstract	(no	
prospective	study	on	the	association	between	
thyroid	hormones	and	atrial	fibrillation)														
(n	=	1352)	
IPD	
Studies	included	(n	=	11)	
Participants	included	(n	=	30,085)	
Participants	excluded	(n	=	20,987)	
because	of	not	meeting	inclusion	
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Full-text	articles	excluded	(n	=	34)	due	to:	‡	
Review,	meeting	abstract,	poster	or	
editorial	(n	=	10)		
No	prospective	cohort	study	(n	=	8)	
No	measurement	of	both	serum	TSH	and	
thyroxine	at	baseline	(n	=	2)	
No	explicit	assessment	of	atrial	fibrillation	
outcome	events	(n	=	9)	
Studies	assessing	only	postoperative	atrial	
fibrillation	events	(n	=	5)	
Full-text	articles	assessed	for	eligibility	
(n	=	48)	
Records	after	duplicates	removed									
(n	=	1400)	
Studies	for	which	IPD	were	not	or	not	fully	
provided	(n	=	2)	||	
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Studies	for	which	IPD	were	provided				
(n	=	11)	
Participants	from	whom	data	were	
provided	(n	=	51,072)	
Participants	for	whom	no	data	were	
provided	(n	=	0)	
Studies	for	which	aggregate	data	were	available	
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Aggregate	data	
Studies	included	in	analysis	(n	=	2)		
Participants	included	(n	=	10,499)	#	
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(n	=	14)	
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Figure	Legends	
Supplemental	Figure	1.	Selection	of	the	final	study	population	for	the	individual	participant	data	analysis.		
Abbreviations:	AF,	atrial	fibrillation;	fT4,	free	thyroxine;	TSH,	thyroid	stimulating	hormone.	
Supplemental	Figure	2.	Study	flow	diagram.	Studies	evaluated	for	inclusion	in	the	IPD	analysis,	adapted	from	
PRISMA-IPD	Statement	Flow	Diagram.3		Abbreviations:	IPD,	individual	participant	data	
*	Until	July	27,	2016	
†	from	prospective	cohorts	participating	in	the	international	Thyroid	Studies	Collaboration	that	had	prospective	
data	on	atrial	fibrillation	outcomes	
‡	List	of	excluded	full	text	articles	in	Supplemental	Table	2	
§Two	articles	retrieved	through	database	searching	included	the	same	population	of	the	Cardiovascular	Health	
Study	4,5	
||	Data	on	1759	euthyroid	and	subclinically	hypothyroid	participants	from	the	Framingham	Heart	Study	6	were	
not	provided	free	of	charge.		Among	the	8740	participants	included	in	the	Rotterdam	Study,7	data	of	the	1426	
participants	included	in	the	Rotterdam	Study	Cohort	I	that	had	been	previously	published	8	were	provided,	
whereas	data	on	7314	participants	of	the	Rotterdam	Study	Cohorts	II	and	III	were	not	provided.	
#	Chaker	and	colleagues	reported	aggregate	data	of	the	Rotterdam	Study	Cohorts	I,	II,	and	III,	therefore	the	
individual	participant	data	of	Rotterdam	Cohort	I	(that	were	included	in	our	main	analysis)	were	excluded	for	
the	sensitivity	analysis	including	the	aggregate	data.7	
Supplemental	Figure	3.	Restricted	cubic	spline	plot	for	the	association	between	continuous	concentrations	of	
thyroid	stimulating	hormone	and	atrial	fibrillation.	The	p-value	for	a	non-linear	trend	was	0.067.	Abbreviations:	
TSH,	thyroid	stimulating	hormone.		
Supplemental	Figure	4.	Restricted	cubic	spline	plot	for	the	association	between	continuous	concentrations	of	
free	thyroxine	within	the	reference	range	and	atrial	fibrillation.	The	p-value	for	a	non-linear	trend	was	£0.001.	
Abbreviations:	fT4,	free	thyroxine;	SD,	standard	deviation.		
Supplemental	Figure	5.	Funnel	plot	for	the	association	between	free	thyroxine	within	the	reference	range	and	
atrial	fibrillation.	Estimates	of	the	highest	fT4	quartile	compared	to	the	lowest	fT4	quartile	were	considered.	
Abbreviations:	fT4,	free	thyroxine;	SE,	standard	error.	
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